Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | DPP4 | P27487 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | RORA | P35398 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | RORB | Q92753 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5233021 | 0.85 | DPP4 (0.44) | SMN1; SMN2NPSR1DPP4TDP1MAPT | |
| SCHEMBL5237977 | 0.83 | TSHR (0.41) | SMN1; SMN2NPSR1TSHRPTK2BKMT2A | |
| SCHEMBL5237189 | 0.83 | DPP4 (0.50) | SMN1; SMN2NPSR1DPP4TSHRTDP1 | |
| SCHEMBL5233023 | 0.82 | DPP4 (0.49) | SMN1; SMN2NPSR1DPP4TSHRTDP1 | |
| SCHEMBL5276978 | 0.82 | TSHR (0.40) | SMN1; SMN2NPSR1TSHRPTK2BMAPT | |
| Hydrochloric Acid SCHEMBL5240215 | 0.81 | DPP4 (0.59) | SMN1; SMN2NPSR1DPP4TSHRTDP1 | |
| SCHEMBL5237718 | 0.81 | TSHR (0.42) | SMN1; SMN2NPSR1TSHRPTK2BTDP1 | |
| SCHEMBL5237304 | 0.81 | TSHR (0.43) | NPSR1TSHRPTK2BKMT2AGABRA1 | |
| SCHEMBL5234899 | 0.80 | NPSR1 (0.45) | SMN1; SMN2NPSR1DPP4TSHRPTK2B | |
| SCHEMBL5266554 | 0.79 | TSHR (0.40) | SMN1; SMN2NPSR1TSHRPTK2BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | SMN1; SMN2 4002/4885NPSR1 2290/4885DPP4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.